Short radiation plus immunotherapy before esophageal cancer surgery
Part of Cancer, Digestive system clinical trials.
This trial tests a short course of radiation combined with the immunotherapy drug Sintilimab before surgery for esophageal cancer. The goal is to see if this combination makes the tumor shrink more and improves treatment results.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have a type of esophageal cancer called squamous cell carcinoma, confirmed by biopsy.
- Your cancer is considered resectable (can be removed by surgery) and is at stage T3, T4, or has spread to nearby lymph nodes (N+).
- You have at least one tumor that can be measured on scans.
- You are in good overall health (ECOG score 0 or 1, meaning you can carry out daily activities without help).
- Your major organs (like heart, lungs, liver, kidneys) are working well enough for the treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a combination of an immunotherapy drug (sintilimab) with chemotherapy given before surgery for a type of esophageal cancer called squamous cell carcinoma. The goal is to see if this treatment shrinks the tumor and improves outcomes.
This trial tests different doses of radiation therapy combined with an immunotherapy drug called sintilimab for people with advanced esophageal cancer that hasn't spread far. The goal is to find the best dose to shrink tumors and improve outcomes.
This Phase 3 trial studies whether adding sintilimab (an immunotherapy medicine) after surgery improves outcomes for people with locally advanced esophageal squamous cell carcinoma. It compares sintilimab plus a chemo/RT plan versus the same chemo/RT plan without immunotherapy.
This trial tests whether giving the immunotherapy drug sintilimab together with standard chemotherapy and a growth factor injection before surgery can help people with a certain type of esophageal cancer (squamous cell carcinoma) that is still removable. The goal is to improve treatment outcomes before the operation.
This trial tests giving the immunotherapy drug sintilimab together with chemotherapy before and after surgery for esophageal squamous cell carcinoma. It aims to see if this combination can help improve outcomes for patients whose tumors can be surgically removed.
This trial looks at adding sintilimab (an immunotherapy) after surgery for certain stages of esophageal squamous cell cancer. The goal is to lower the chance the cancer comes back after standard treatment.
Hear when a new Esophageal Squamous Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.